Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Eisai, NCC Strike Drug Discovery Deal on Rare/Refractory Cancers
May 17, 2021
- Astellas/Seagen’s ADC Enfortumab Vedotin Gets Priority Review in Japan
May 17, 2021
- Astellas, Kyoto University VC Pair Up on Cross-Disciplinary Drug Discovery
May 17, 2021
- FY2020 Sales of 7 Major Japan Drug Makers Slip 2.7% on COVID-19, Price Woes: Tally
May 14, 2021
- Japan Ethical Drug Sales Up 5.7% in March: Crecon
May 14, 2021
- Opdivo Top-Selling Drug in Japan in April: Encise
May 14, 2021
- Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
May 14, 2021
- Daiichi Sankyo Seeks Central Neuropathic Pain Use for Tarlige
May 14, 2021
- Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
May 14, 2021
- Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President
May 14, 2021
- Mitsubishi Tanabe Incurs Operating Loss 2 Years Running as Parkinson’s Write-Down Weighs
May 13, 2021
- Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
May 13, 2021
- Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
May 13, 2021
- Sawai Group Aims to Double Sales to 400 Billion Yen by FY2030: New Long-Term Vision
May 13, 2021
- 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
May 13, 2021
- Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
May 12, 2021
- Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
May 12, 2021
- Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
May 12, 2021
- Fuji Yakuhin Out-Licenses Hyperuricemia Med Dotinurad to US Biotech
May 12, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…